Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption

More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes. Policymakers who “wish to decrease the rewards for repurposing a common disease drug to treat rare disease” might consider limiting the 340B discount exemption “to instances in which the drug is used for the rare disease for which it has orphan drug designation,” the researchers said.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga